Table 352

• Minimal residual disease status at time of harvest

• Disease status at time of transplant (initial remission, second remission, etc.)

• Time from achievement of remission to transplant

• Post-remission chemotherapy prior to harvest (in AML)

FLT3-ITD: fms-like tyrosine kinase 3-internal tandem duplication mutation.

remissions in more than 40% of patients treated with the most dose-intensive regimens.6 These data strongly suggested that increasing intensity of postremission therapy was a critical strategy to achieve cure of AML. SCT was the logical progression of this idea: administering myeloablative doses of CT, hopefully toxic enough to leukemic cells that hematopoietic stem cell (HSC) replacement was necessary for marrow recovery.

0 0

Post a comment